UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications.
First-line drug treatment for tuberculosis (TB) is frequently associated with liver toxicity. The goal of this study was to examine the association between UDP-glucuronosyl-transferase 1A1 (UGT1A1) genetic variations and anti-tuberculosis drug-induced hepatotoxicity (ATDH). A  total of 98 patients, including 17 patients with ATDH, were enrolled; compound UGT1A1*27 and UGT1A1*28 were associated with an increased risk for developing ATDH after adjusting for age (OR 13.859; 95%CI 1.085-177.056). These findings require confirmation. However, screening  for genetic variations prior to TB treatment may reduce the incidence of ATDH and improve treatment adherence.
Department of Pharmacy, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
J-C
JC
Chang
E H
EH
Liu
C-N
CN
Lee
Y-C
YC
Lin
M-C
MC
Yu
K-J
KJ
Bai
H-Y
HY
Chen
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000995:Antitubercular Agents / Q000009:adverse effects* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology* / Q000235:genetics; D005260:Female; D020022:Genetic Predisposition to Disease; D014453:Glucuronosyltransferase / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D012189:Retrospective Studies; D012307:Risk Factors; D014376:Tuberculosis / Q000188:drug therapy*; D000099148:UGT1A1 Enzyme
D000995:Antitubercular Agents; D014453:Glucuronosyltransferase; D000099148:UGT1A1 Enzyme